AZN:NYE-Astrazeneca PLC

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 36.13

Change

+0.19 (+0.53)%

Market Cap

USD 91.53B

Volume

1.73M

Yahoo Analyst Target

USD 39.09 (8.19%)

STA Analyst Target

USD 38.25 (5.86%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-06-20 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

-0.53 (-0.43%)

USD 327.33B
PFE Pfizer Inc.

+0.24 (+0.66%)

USD 213.28B
NVS Novartis AG

+0.66 (+0.90%)

USD 173.02B
MRK Merck & Company Inc. (new)

+0.25 (+0.41%)

USD 164.86B
ABBV AbbVie Inc.

+0.24 (+0.24%)

USD 155.91B
GSK GlaxoSmithKline PLC

-0.01 (-0.02%)

USD 101.74B
SNY Sanofi American Depositary Sha..

+0.29 (+0.74%)

USD 97.79B
LLY Eli Lilly and Company

-0.54 (-0.62%)

USD 93.65B
BMY Bristol-Myers Squibb Company

+0.61 (+1.14%)

USD 88.67B
AGN Allergan plc

+2.14 (+1.24%)

USD 59.40B

ETFs Containing AZN

HHL:CA Harvest Healthcare Leader.. 5.59 % 1.24 %

+0.03 (+0.37%)

CAD 0.26B
PPH VanEck Vectors Pharmaceut.. 5.50 % 0.35 %

+0.37 (+0.61%)

USD 0.29B
LIFE.B:CA Evolve Global Healthcare .. 5.20 % 0.00 %

N/A

CAD 0.49M
LIFE:CA Evolve Global Healthcare .. 5.20 % 0.00 %

N/A

CAD 0.93M
CNCR Loncar Cancer Immunothera.. 3.17 % 0.79 %

+0.51 (+1.98%)

USD 0.07B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.12% 62% D- 74% C
Dividend Return 2.74% 91% A- 78% C+
Total Return 6.86% 62% D- 77% C+
Trailing 12 Months  
Capital Gain 4.06% 57% F 56% F
Dividend Return 4.00% 85% B 61% D-
Total Return 8.06% 71% C- 57% F
Trailing 5 Years  
Capital Gain 49.67% 79% C+ 70% C-
Dividend Return 28.67% 100% A+ 76% C
Total Return 78.33% 79% C+ 75% C
Average Annual (5 Year Horizon)  
Capital Gain 5.32% 57% F 60% D-
Dividend Return 9.74% 67% D+ 64% D
Total Return 4.43% 93% A 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 19.51% 57% F 37% F
Risk Adjusted Return 49.92% 67% D+ 46% F
Market Capitalization 65.58B 65% D 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.10 67% D+ 42% F
Price/Book Ratio 2.70 52% F 35% F
Price / Cash Flow Ratio 1.97 81% B- 64% D
Price/Free Cash Flow Ratio 84.02 5% F 6% F
Management Effectiveness  
Return on Equity 16.48% 71% C- 75% C
Return on Invested Capital 11.58% 52% F 65% D
Return on Assets 3.91% 62% D- 60% D-
Debt to Equity Ratio 114.25% 35% F 34% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

AZN:NYE-Astrazeneca PLC

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 36.13

Change

+0.19 (+0.53)%

Market Cap

USD 91.53B

Volume

1.73M

Yahoo Analyst Target

USD 39.09 (8.19%)

STA Analyst Target

USD 38.25 (5.86%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-06-20